Tumor-associated calcium signal transducer 2 (TACSTD2)

Overview

tumor-associated calcium signal transducer 2 (TROP2), encoded by the TACSTD2 gene and also known as trophoblast cell-surface antigen 2 (Trop-2), is a type I transmembrane glycoprotein that was originally identified on trophoblast cells of the placenta. It functions as a calcium signal transducer and is implicated in the regulation of cell proliferation, survival, and adhesion. Under normal physiological conditions, TROP2 expression is restricted to a limited set of epithelial tissues; however, it is broadly and frequently overexpressed across a wide range of solid tumors, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), pancreatic cancer, and breast, gastric, and urothelial carcinomas. This tumor-enriched expression pattern, combined with its extracellular accessibility as a membrane-bound antigen, makes TROP2 a highly attractive therapeutic target.

The protein's association with cancer invasiveness and poorer patient outcomes has driven extensive efforts to exploit it as an antibody-drug conjugate (ADC) target. Several TROP2-directed ADCs have advanced through clinical development, with at least one receiving regulatory approval from both the Food and Drug Administration (FDA) and China's National Medical Products Administration (NMPA) for use in patients with acquired resistance to third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). Beyond ADCs, TROP2 is now being explored in radioimmunotherapy, bispecific antibody formats, and proteolysis-targeting chimera (PROTAC)-based platforms, reflecting its versatility as an oncological target.

Recent Publications Focus

Recent studies have continued to evaluate TROP2 as a therapeutic target and biomarker across several tumor types, with particular emphasis on antibody-drug conjugates (ADCs) and on how target expression changes over time or under treatment pressure. In metastatic breast cancer, serial immunohistochemical analysis of 229 samples from 76 patients showed that TROP2 expression was generally high and largely stable across biopsy time points, although a subset of patients had substantial declines during disease progression; in paired pre- and post-sacituzumab govitecan samples, the mean H-score decreased modestly but not significantly, and exploratory progression-free survival analysis did not show a significant association with post-treatment TROP2 change 42467304Jul. In a separate breast cancer liquid-biopsy study, single-cell profiling of circulating tumor cells and paired tumor biopsies found marked heterogeneity in TROP2 expression, but baseline TROP2 levels on circulating tumor cells did not predict response to TROP2- or HER2-directed ADCs; instead, early reduction in circulating tumor cell burden was associated with durable benefit, suggesting that payload sensitivity may be more informative than target abundance alone 42308036Jun.

Several publications focused on TROP2 in lung cancer, especially in the setting of epidermal growth factor receptor (EGFR)-mutant disease and resistance to tyrosine kinase inhibitors. One preclinical and translational study found that TROP2 is dynamically upregulated during the formation of drug-tolerant persister cells after epidermal growth factor receptor (EGFR) TKI exposure, where it contributes functionally to persister-cell maintenance; mechanistically, c-MYC proto-oncogene (MYC) acted as a transcriptional repressor of TROP2, and MAPK pathway inhibition reduced c-MYC proto-oncogene (MYC), leading to TROP2 upregulation 42314664Jun. In preclinical models, combining the TROP2-targeting ADC sacituzumab tirumotecan with osimertinib suppressed persister-cell emergence and delayed relapse, and the authors noted preliminary efficacy from an ongoing phase 2 trial of first-line sac-TMT plus osimertinib in advanced epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer 42314664Jun. A related commentary highlighted this work as support for an “induce-target-kill” strategy in drug-tolerant persister cells 42314666Jun. Another phase 3 trial in PD-L1-positive advanced non-small-cell lung cancer evaluated sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab alone as first-line therapy, reflecting continued clinical development of TROP2-directed combinations in lung cancer 42214392May. Additional lung cancer studies included comparative target-expression analyses in small cell lung carcinoma and AI-based profiling approaches for ADC target assessment in non-small-cell lung cancer, both of which included TROP2 among the therapeutic targets under study 42013561Apr41945491Apr.

Beyond breast and lung cancer, TROP2 was also examined as part of broader biomarker and target-expression efforts in ovarian cancer and pan-cancer proteomics. An ovarian cancer study assessed HER2, nectin-4, and TROP2 expression across histotypes to inform patient selection for ADCs, noting that antigen expression may vary significantly by histotype. In pan-cancer proteomics, a bimodality analysis identified TROP2 as one of many tumor-associated bimodal proteins and, in a colon adenocarcinoma case study, TROP2-high tumors showed upregulation of MYC proto-oncogene (MYC) and WNT/β-catenin pathways with downregulation of inflammatory pathways 42426806Jul. Another proteomics study in metastatic prostate cancer detected Trop-2 among extracellular vesicle-derived cell-surface proteins, with higher levels of these proteins associated with worse overall survival and correlated with imaging and laboratory measures of disease burden 42013849Apr.

Mechanistic work also linked TROP2 to oncogenic signaling states and therapeutic vulnerabilities. In pancreatic ductal adenocarcinoma, prolonged Kras-MAPK inhibition induced an interferon/NF-κB-driven cell-state transition with EMT-like features, accompanied by marked upregulation of TROP2 (TACSTD2); combining sacituzumab govitecan with KRAS or ERK inhibitors significantly suppressed tumor growth in xenograft models 42008116Apr. In another preclinical study, TROP2 was used as a tumor-specific surface marker to build a TROP2-targeted anti-Frizzled bispecific antibody that inhibited Wnt signaling while minimizing toxicity to normal intestinal tissue 42172336May. Together, these publications portray TROP2 as a widely expressed but context-dependent target that is being explored both as a direct ADC antigen and as a platform for tumor-selective combination strategies 41730505Feb.

What Changes, What Holds

1. TROP2 remains a generally stable biomarker in metastatic breast cancer, but target abundance alone is not enough to predict ADC benefit
REINFORCES Serial sampling supports the baseline view of TROP2 as broadly expressed in breast cancer, while also showing that expression can fall in a subset during progression and after sacituzumab govitecan exposure 42467304Jul. The more important implication is negative: changing TROP2 levels did not clearly track progression-free survival, and baseline circulating-tumor-cell TROP2 did not predict response in the liquid-biopsy study 42308036Jun. That weakens any simple “more target, more benefit” model and points toward payload sensitivity or early tumor-burden change as more useful response markers.

2. EGFR-TKI pressure can induce TROP2 and create a combination-therapy vulnerability in lung cancer
NEW DIRECTION This work extends the lung-cancer story beyond static overexpression by showing that TROP2 can be dynamically induced during drug-tolerant persister-cell formation after EGFR TKI exposure 42314664Jun. That does not overturn TROP2 as a target, but it changes how the target should be understood in resistant disease: it may be part of the persister-state machinery rather than just a passive marker. The reported benefit of pairing sacituzumab tirumotecan with osimertinib fits that model, although the evidence is still preclinical/translational and needs prospective confirmation in EGFR-mutant NSCLC 42314664Jun.

3. TROP2 is being used as a context-dependent selection marker across additional tumor types and proteomic states
REINFORCES These studies do not change the baseline claim that TROP2 is a broadly useful tumor antigen; instead, they sharpen the point that expression is heterogeneous and histotype- or state-dependent42426806Jul. The ovarian-cancer and pan-cancer proteomics data mainly argue for better patient selection and for interpreting TROP2 alongside broader pathway programs such as MYC and WNT/β-catenin, rather than treating it as a uniform marker across all tumors. The prostate extracellular-vesicle finding similarly supports its value as a disease-burden-associated surface protein, not a new biological role.

4. Oncogenic signaling states can induce TROP2 and create new combination opportunities, while bispecific targeting broadens its therapeutic use
NEW DIRECTION This paragraph adds a mechanistic layer not covered in the baseline: TROP2 is not only overexpressed in tumors, it can be induced by pathway inhibition and linked to state transitions such as EMT-like programs in pancreatic cancer 42008116Apr. That matters because it suggests TROP2 may mark or help sustain adaptive resistance states, making ADC combinations with KRAS/ERK inhibition biologically rational. The anti-Frizzled bispecific also expands the baseline’s therapeutic framing by using TROP2 as a tumor-selective anchor for another pathway-directed modality 42172336May.

Overview update candidates: TROP2 expression is often stable but can decline during progression; abundance alone may not predict ADC response; TROP2 can be upregulated by EGFR-TKI pressure and may help sustain persister cells; combination with osimertinib is a plausible resistance strategy; TROP2 can be induced by KRAS/MAPK inhibition in pancreatic cancer and may support combination strategies; TROP2 can serve as a tumor-selective platform for bispecific antibodies.